


PROTEINURIA FACTSHEET



THE SIGNS AND SYMPTOMS OF IgA NEPHROPATHY (IgAN) ARE VARIABLE:¹⁻⁵



Proteinuria



Macrohematuria



Renal insufficiency



Hypertension



Acute kidney injury




Edema

However, patients may be asymptomatic^{1,2}

In these cases, IgAN may only be detected by routine testing

IN PATIENTS WITH IgAN, THE AVERAGE KIDNEY SURVIVAL TIME IS **11.4 YEARS**, WITH MOST PATIENTS REACHING **KIDNEY FAILURE WITHIN 10-15 YEARS**^{6*}

PROTEINURIA IS A KEY FEATURE OF IgAN:



1. Key marker and predictor

Proteinuria is a modifiable prognostic indicator for kidney damage and identifies patients at an increased risk of progression to kidney failure^{7,8}

2. Contributor

Proteinuria plays a critical role in accelerating disease progression to kidney failure through various pathologic processes^{9,10}

3. Prognostic value

Time-average proteinuria is associated with worse kidney survival and more rapid eGFR loss in IgAN⁶

4. Protective effect

The more proteinuria is reduced, the greater the protective effect against decline in kidney function^{1,6-9}

EARLIER IDENTIFICATION OF PATIENTS AT A HIGH RISK OF DISEASE PROGRESSION MAY IMPROVE OUTCOMES^{2,8}

The International Risk Prediction Tool[†] for IgAN and the MEST-C[‡] score can also be used to identify patients at risk of disease progression¹¹⁻¹³

KDIGO USES PROTEINURIA TO DEFINE REMISSION IN IgAN¹¹

The KDIGO Guidelines defines high risk of progression in IgAN as **proteinuria >0.75-1g/day**, despite at least 90 days of optimized supportive care¹¹

TO SLOW PROGRESSION TO KIDNEY FAILURE TARGET PROTEINURIA

Visit targetproteinuria.com for more information

*The IgA nephropathy cohort of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed retrospectively (N=2439). Median follow-up was 5.9 years.⁶ †The International IgAN Risk Prediction Tool recommended by the KDIGO Guidelines incorporates clinical and histologic parameters: proteinuria, eGFR, and blood pressure at time of biopsy; use of ACE inhibitor or ARB at the time of biopsy or immunosuppression use at or prior to biopsy; patient characteristics: age at time of biopsy and race; and histologic features: MEST. It has been updated and validated, accounting for the unique disease trajectory in children as well as use of the tool up to 2 years post-biopsy.¹²⁻¹³ ‡The MEST-C (mesangial and endocapillary hypercellularity, segmental sclerosis, interstitial fibrosis/tubular atrophy, and crescents) score is a histopathological scoring system for patients with IgAN. The MEST-C score should be determined at the time of biopsy and is an important practice point for the diagnosis of IgAN¹¹

ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; IgAN, IgA nephropathy; KDIGO, Kidney Disease: Improving Global Outcomes; MEST, mesangial and endocapillary hypercellularity, segmental sclerosis and interstitial fibrosis/tubular atrophy; MEST-C, Oxford classification MEST-C; RaDaR, Registry of Rare Kidney Diseases

1. Wyatt R, Julian B. *N Engl J Med* 2013;368:2402-14. 2. Lai KN, et al. *Nat Rev Dis Primers* 2016;2:16001. 3. Penfold RS, et al. *Int J Nephrol Renovasc Dis* 2018;11:137-48. 4. Rodrigues JC, et al. *Clin J Am Soc Nephrol* 2017;12:677-86. 5. Yeo SC, et al. *Nephrology* 2019;24:885-95. 6. Pitcher D, et al. *Clin J Am Soc Nephrol* 2023;18(6):727-38. 7. Inker LA, et al. *Am J Kidney Dis* 2016;68(3):392-401. 8. Reich HN, et al. *J Am Soc Nephrol* 2007;18:3177-83. 9. Sharma S, Smyth B. *Kidney Blood Press Res* 2021;46:411-20. 10. Cravedi P, et al. *Br J Clin Pharmacol* 2013;76(4):516-23. 11. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. *Kidney Int* 2021;100:S1-276. 12. Barbour S, et al. *JAMA Intern Med* 2019;179:942-52. 13. Barbour S, et al. *Kid Int* 2022;102:160-72.